# US 2024/0197748 A1 · Combination treatment for melanoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197748 A1
- Document ID: US20240197748A1
- Status: Published application
- Kind: A1
- Application number: 18/552,300
- Filed: 2022-03-25
- Published: 2024-06-20
- Earliest claimed: 2021-03-26
- Assignees: AstraZeneca AB
- Applicants: AstraZeneca AB
- Inventors: Simon Andrew SMITH; Emma Jane DEAN; Jeeyun LEE
- Web page: https://patentgrep.com/patent/US20240197748A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Combination Treatments for Melanoma This specification discloses the use of an ATR inhibitor in combination with an immune checkpoint inhibitor for the treatment of melanoma in a patient who has previously received immunotherapy.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of treating melanoma in a human or animal patient, who has previously received immunotherapy, in need of such treatment, comprising administering to said patient an effective amount of an ATR inhibitor in combination with an effective amount of an immune checkpoint inhibitor.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The method according to claim 2, wherein the ATR inhibitor is selected from the group consisting of AZD6738, M6620 (berzosertib), BAY-1895344, EPT-46464, VE-821 and VX-970.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the ATR inhibitor is AZD6738.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the immune checkpoint inhibitor is a PD-1 inhibitor, a PD-L1 inhibitor or a CTLA-4 inhibitor.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the immune checkpoint inhibitor is a PD-L1 inhibitor.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the PD-L1 inhibitor is durvalumab or an antigen-binding fragment thereof.

### Claim 9 (depends on 2)

The method according to claim 2, wherein the melanoma is selected from the group consisting of cutaneous, acral and mucosal melanoma.

### Claim 10 (depends on 2)

The method according to claim 2, wherein the melanoma is advanced melanoma.

### Claim 11 (depends on 2)

The method according to claim 2, wherein the melanoma is metastatic melanoma.

### Claim 12 (depends on 5)

The method according to claim 5, wherein AZD6738 is administered on days 15 to 28 of a 28-day cycle.

### Claim 13 (depends on 5)

The method according to claim 5, wherein AZD6738 is administered on days 1 to 7 of a 28-day cycle.

### Claim 14 (depends on 5)

The method according to claim 5, wherein total daily dose of AZD6738 is between 30 mg and 500 mg.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the total daily dose of AZD6738 is administered twice daily in 240 mg doses.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the total daily dose of AZD6738 is administered twice daily in 160 mg doses.

### Claim 17 (depends on 8)

The method according to claim 8, wherein durvalumab is administered in an amount of 1500 mg once every 4 weeks from cycle 1 day 1.

### Claim 18 (depends on 2)

The method according to claim 2, wherein the previous immunotherapy comprises treatment with an immune checkpoint inhibitor.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the previous immunotherapy comprises treatment with an immune checkpoint inhibitor is selected from a PD-1 inhibitor, PD-L1 inhibitor and a CTLA-4 inhibitor.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the previous immunotherapy comprises treatment with an immune checkpoint inhibitor is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, spartalizumab, camrelizumab, sintilimab, tislelizumab, toripalimab, AMP-224, AMP-514, atezolizumab, avelumab, durvalumab, KN035, CK-301, AUNP12, CA-170, BMS-986189, ipilimumab and tremelimumab.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the previous immunotherapy comprises treatment with pembrolizumab or nivolumab.

### Claim 22 (depends on 2)

The method according to claim 2, wherein the patient has primary resistance to immunotherapy.

### Claim 23 (depends on 2)

The method according to claim 2, wherein the patient has acquired resistance to immunotherapy.

### Claim 24 (depends on 2)

The method according to claim 2, wherein the patient received immunotherapy as adjuvant therapy.

### Claim 25 (depends on 2)

The method according to claim 2, wherein the treatment achieves an objective response rate greater than 30%.

### Claim 26 (depends on 2)

The method according to claim 2, wherein progression free survival is greater than 3 months.

### Claim 27 (depends on 2)

The method according to claim 2, where overall survival is greater than 10 months.

### Claim 28 (depends on 2)

The method according to claim 2, wherein duration of response is at least 3 months.

### Claim 29

A kit comprising:
a. a first pharmaceutical composition comprising an ATR inhibitor and a pharmaceutically acceptable excipient;
b. a second pharmaceutical composition comprising an immune checkpoint inhibitor and a pharmaceutically acceptable excipient; and instructions for the use of the use of the first and second pharmaceutical compositions in the treatment of melanoma in a patient who has previously received immunotherapy.
